A Study of AK130 in Patients With Advanced Malignant Tumors
A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of AK130 (TIGIT/TGF-β bifunctional fusion protein) in patients with advanced malignant tumors.
Advanced Malignant Tumors
DRUG: AK130
Incidence and severity of participants with adverse events (AEs), From time ICF is signed until 90 days after last dose of AK130|Number of participants with DLTs, During the first four weeks of treatment with AK130
Objective response rate (ORR), Up to approximately 2 years|Disease control rate (DCR), Up to approximately 2 years|Progression-free survival (PFS), Up to approximately 2 years|Overall survival (OS), Up to approximately 2 years|Duration of Response (DOR), Up to approximately 2 years|Time to response (TTR), Up to approximately 2 years|Maximum observed concentration (Cmax) of AK130, The endpoints for assessment of PK include serum concentrations of AK130 at different timepoints after AK130 administration., From first dose of study drug through end of treatment (up to approximately 2 years)|Minimum observed concentration(Cmin) of AK130, The endpoints for assessment of PK include serum concentrations of AK130 at different timepoints after AK130 administration., From first dose of study drug through end of treatment (up to approximately 2 years)|Area under the curve (AUC) of AK130 for assessment of pharmacokinetics, The endpoints for assessment of PK include serum concentrations of AK130 at different timepoints after AK130 administration., From first dose of study drug through end of treatment (up to approximately 2 years)|Number of subjects who develop detectable anti-drug antibodies (ADAs), From first dose of study drug through 30 days after last dose of study drug
A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of AK130 (TIGIT/TGF-β bifunctional fusion protein) in patients with advanced malignant tumors.